Ticagrelor versus aspirin and vein graft patency after coronary bypass: a randomized trial

A Kulik, AM Abreu, V Boronat… - Journal of Cardiac …, 2022 - Wiley Online Library
Background Antiplatelet therapy prevents saphenous vein graft (SVG) occlusion and
improves outcomes after coronary artery bypass graft surgery (CABG). However, the optimal …
被引用次数：19 相关文章

[引用][C] Ticagrelor versus aspirin and vein graft patency after coronary bypass: A randomized trial

A Kulik, V Boronat, A Abreu - 2022 - scholarlycommons.baptisthealth.net
"Ticagrelor versus aspirin and vein graft patency after coronary bypass" by Alexander Kulik,
Viviana Boronat et al. Home Search Browse Collections My Account About DC Network Digital …

Ticagrelor versus aspirin and vein graft patency after coronary bypass: A randomized trial.

A Kulik, AM Abreu, V Boronat… - Journal of Cardiac …, 2022 - search.ebscohost.com
Background: Antiplatelet therapy prevents saphenous vein graft (SVG) occlusion and
improves outcomes after coronary artery bypass graft surgery (CABG). However, the optimal …

Ticagrelor versus aspirin and vein graft patency after coronary bypass: A randomized trial.

A Kulik, AM Abreu, V Boronat… - Journal of Cardiac …, 2021 - europepmc.org
Background Antiplatelet therapy prevents saphenous vein graft (SVG) occlusion and
improves outcomes after coronary artery bypass graft surgery (CABG). However, the optimal …

Ticagrelor versus aspirin and vein graft patency after coronary bypass: A randomized trial

A Kulik, AM Abreu, V Boronat, NT Kouchoukos, M Ruel - 2022 - pubmed.ncbi.nlm.nih.gov
Background Antiplatelet therapy prevents saphenous vein graft (SVG) occlusion and
improves outcomes after coronary artery bypass graft surgery (CABG). However, the optimal …